HomeCompareGILD vs EMN

GILD vs EMN: Dividend Comparison 2026

GILD yields 2.34% · EMN yields 4.60%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EMN wins by $33.4K in total portfolio value
10 years
GILD
GILD
● Live price
2.34%
Share price
$136.34
Annual div
$3.19
5Y div CAGR
17.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.1K
Annual income
$1,614.90
Full GILD calculator →
EMN
EMN
● Live price
4.60%
Share price
$72.55
Annual div
$3.34
5Y div CAGR
25.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$62.5K
Annual income
$11,712.17
Full EMN calculator →

Portfolio growth — GILD vs EMN

📍 EMN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGILDEMN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GILD + EMN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GILD pays
EMN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GILD
Annual income on $10K today (after 15% tax)
$198.88/yr
After 10yr DRIP, annual income (after tax)
$1,372.67/yr
EMN
Annual income on $10K today (after 15% tax)
$391.32/yr
After 10yr DRIP, annual income (after tax)
$9,955.34/yr
At 15% tax rate, EMN beats the other by $8,582.68/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GILD + EMN for your $10,000?

GILD: 50%EMN: 50%
100% EMN50/50100% GILD
Portfolio after 10yr
$45.8K
Annual income
$6,663.54/yr
Blended yield
14.54%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GILD right now

GILD
Analyst Ratings
37
Buy
20
Hold
1
Sell
Consensus: Buy
Price Target
$158.71
+16.4% upside vs current
Range: $105.00 — $180.00
Altman Z
4.1
Piotroski
8/9
EMN
Analyst Ratings
20
Buy
14
Hold
1
Sell
Consensus: Buy
Price Target
$74.00
+2.0% upside vs current
Range: $70.00 — $79.00
Altman Z
2.3
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GILD buys
0
EMN buys
0
No recent congressional trades found for GILD or EMN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGILDEMN
Forward yield2.34%4.60%
Annual dividend / share$3.19$3.34
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR17.3%25.7%
Portfolio after 10y$29.1K$62.5K
Annual income after 10y$1,614.90$11,712.17
Total dividends collected$7.6K$36.8K
Payment frequencyquarterlyquarterly
SectorHealthcareMaterials
Analyst consensusBuyBuy
Analyst price target$158.71$74.00

Year-by-year: GILD vs EMN ($10,000, DRIP)

YearGILD PortfolioGILD Income/yrEMN PortfolioEMN Income/yrGap
1← crossover$10,974$274.45$11,279$578.69$305.00EMN
2$12,073$330.19$12,835$766.75$762.00EMN
3$13,316$398.20$14,758$1,025.04$1.4KEMN
4$14,730$481.49$17,176$1,384.65$2.4KEMN
5$16,345$583.87$20,272$1,893.11$3.9KEMN
6$18,199$710.26$24,315$2,624.76$6.1KEMN
7$20,340$866.96$29,716$3,698.58$9.4KEMN
8$22,826$1,062.22$37,106$5,310.02$14.3KEMN
9$25,731$1,306.80$47,493$7,789.38$21.8KEMN
10$29,147$1,614.90$62,530$11,712.17$33.4KEMN

GILD vs EMN: Complete Analysis 2026

GILDHealthcare

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Full GILD Calculator →

EMNMaterials

Eastman Chemical Company operates as a specialty materials company in the United States and internationally. The company's Additives & Functional Products segment offers hydrocarbon and rosin resins; organic acid-based solutions; amine derivative-based building blocks; metam-based soil fumigants, thiram and ziram based fungicides, and plant growth regulators; specialty coalescent, specialty and commodity solvents, paint additives, and specialty polymers; heat transfer and aviation fluids; insoluble sulfur and anti-degradant rubber additives; and performance resins. It serves transportation, personal care, wellness, food, feed, agriculture, building and construction, water treatment, energy, consumables, durables, and electronics markets. Its Advanced Materials segment provides copolyesters, cellulosic biopolymers, cellulose esters, polyvinyl butyral (PVB) sheets, and window and protective films, and aftermarket applied film products for value-added end uses in the transportation, durables, electronics, building and construction, medical and pharma, and consumables markets. The company's Chemical Intermediates segment offers methylamines and salts higher amines and solvents; Olefin and acetyl derivatives, ethylene, and commodity solvents; and primary non-phthalate and phthalate plasticizers, and niche non- phthalate plasticizers to the industrial chemicals and processing, building and construction, health and wellness, and agrochemicals. Its Fibers segment provides cellulose acetate tow, triacetin, cellulose acetate flake, acetic acid, and acetic anhydride for use in filtration media primarily cigarette filters; natural and solution dyed acetate yarns for use in consumables, and health and wellness markets; and wet-laid nonwoven media, specialty and engineered papers, and cellulose acetate fibers for transportation, industrial, agriculture and mining, and aerospace markets. Eastman Chemical Company was founded in 1920 and is headquartered in Kingsport, Tennessee.

Full EMN Calculator →
📬

Get this GILD vs EMN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GILD vs SCHDGILD vs JEPIGILD vs OGILD vs KOGILD vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.